The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
Study Type
OBSERVATIONAL
Enrollment
60
Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).
Samsung medical center
Seoul, South Korea
RECRUITINGProgression-free survival
Time from the start of stereotactic body radiotherapy (SABR) to the first documented event of local failure, distant failure, death from any cause, or last follow-up, whichever occurs first.
Time frame: From start of SABR to the earliest of local failure, distant failure, death, or last follow-up. It will be measured at 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
Physician assessed toxicity
Evaluated by treating physician based on CTCAE ver 5.0
Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
Patient-reported outcome
It will be measured by PRO-CTCAE coreset 12.
Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
Local failure
Local regrowth or progression at the site of SABR.
Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
Dynamics of ctDNA
ctDNA analysis
Time frame: It will be collected 1-week before SABR and 4-6 weeks after SABR.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.